Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) saw an uptick in trading volume on Tuesday . 653,026 shares changed hands during mid-day trading, an increase of 22% from the previous session’s volume of 536,895 shares.The stock last traded at $70.05 and had previously closed at $68.10.

Several brokerages have commented on RARE. Morgan Stanley restated a “hold” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, June 8th. Credit Suisse Group AG restated a “buy” rating and issued a $101.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 9th. Leerink Swann restated a “buy” rating and issued a $85.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, July 15th. Canaccord Genuity restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Finally, Jefferies Group restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Sunday, July 17th. Three investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $99.10.

The stock’s market capitalization is $2.55 billion. The firm’s 50 day moving average is $60.03 and its 200 day moving average is $61.82.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.02. During the same quarter in the prior year, the company posted ($0.83) EPS. On average, analysts forecast that Ultragenyx Pharmaceutical Inc. will post ($5.93) EPS for the current fiscal year.

In other Ultragenyx Pharmaceutical news, insider Sunil Agarwal sold 650 shares of the company’s stock in a transaction dated Monday, June 20th. The shares were sold at an average price of $54.16, for a total value of $35,204.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $50.85, for a total transaction of $1,017,000.00. Following the completion of the transaction, the chief executive officer now owns 513,597 shares in the company, valued at $26,116,407.45. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Ultragenyx Pharmaceutical stock. Trexquant Investment LP bought a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 9,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,010,000.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.